Diseases / Atrial Fibrillation
Atrial Fibrillation
DiseaseAtrial fibrillation is a common heart rhythm disorder in which the upper chambers of the heart beat irregularly and often rapidly. It can reduce the heart's pumping efficiency and raise the risk of stroke and other complications.
- Trials
- 3796
- Recruiting
- 466
- Completed
- 1788
- With results
- 497
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 1 | — | — | 3 | 1 | — | — | 2 | — | 9 |
| Phase 1 | 1 | 1 | — | — | 25 | 5 | 2 | — | 4 | — | 38 |
| Phase 1/2 | 1 | 1 | — | — | 6 | 1 | 1 | — | 3 | — | 13 |
| Phase 2 | 12 | 1 | — | 5 | 80 | 12 | 4 | — | 19 | — | 133 |
| Phase 2/3 | 1 | 2 | — | — | 8 | 2 | 2 | — | 3 | — | 18 |
| Phase 3 | 20 | 6 | 1 | 4 | 131 | 29 | 8 | 1 | 35 | — | 235 |
| Phase 4 | 30 | 20 | 2 | 11 | 165 | 33 | 12 | 1 | 71 | — | 345 |
| Not applicable | 244 | 137 | 17 | 88 | 700 | 102 | 49 | 3 | 298 | — | 1638 |
| Unknown | 155 | 73 | 24 | 59 | 670 | 48 | 28 | 2 | 307 | 1 | 1367 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Atrial Fibrillation | 9 | 38 | 13 | 133 | 18 | 235 | 345 | 1638 | 1367 | 3796 |
| Stroke | 2 | 1 | 2 | 10 | 2 | 30 | 29 | 108 | 153 | 337 |
| Arrhythmias, Cardiac | — | 2 | 4 | 7 | 1 | 25 | 13 | 132 | 122 | 306 |
| Heart Failure | — | 1 | 2 | 4 | 1 | 9 | 19 | 86 | 80 | 202 |
| Atrial Flutter | — | — | — | 8 | 3 | 18 | 15 | 56 | 50 | 150 |
| Ischemic Stroke | 1 | — | — | 2 | 1 | 5 | 8 | 45 | 58 | 120 |
| Cardiovascular Diseases | — | — | 1 | 3 | — | 7 | 2 | 41 | 45 | 99 |
| Heart Diseases | — | — | — | 1 | — | 12 | 2 | 30 | 34 | 79 |
| Coronary Artery Disease | — | — | — | 1 | — | 4 | 20 | 20 | 32 | 77 |
| Hypertension | — | — | — | 4 | — | 3 | 6 | 33 | 31 | 77 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Abbott Medical Devices | 64 | 0 |
| 2 | Boston Scientific Corporation | 62 | 5 |
| 3 | Bayer | 59 | 4 |
| 4 | Biosense Webster, Inc. | 49 | 7 |
| 5 | Yonsei University | 48 | 0 |
| 6 | Boehringer Ingelheim | 45 | 3 |
| 7 | Beijing Anzhen Hospital | 34 | 1 |
| 8 | Medtronic Cardiac Ablation Solutions | 32 | 0 |
| 9 | Medtronic Cardiac Rhythm and Heart Failure | 32 | 2 |
| 10 | Mayo Clinic | 30 | 4 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Catheter Ablation | 145 |
| 2 | Rivaroxaban | 113 |
| 3 | Warfarin | 109 |
| 4 | Dabigatran | 81 |
| 5 | apixaban | 80 |
| 6 | Amiodarone | 67 |
| 7 | Radiofrequency Ablation | 59 |
| 8 | edoxaban | 55 |
| 9 | Left Atrial Appendage Closure | 37 |
| 10 | Aspirin | 33 |
Evidence
- Results reported
- 27.8%497 of 1788 completed
- Published
- 16.9%303 of 1788 completed
- Primary endpoint met
- 59.4%303 of 510 analyses
- Median months to report
- 13
Documents disclosed
Trial profile
- Median enrollment
- 168
- Median duration
- 32.5months
- Countries
- 108
- Study sites
- 28222
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 63
- Phase 1
- 40
- Phase 1/2
- 80
- Phase 2
- 104
- Phase 2/3
- 174
- Phase 3
- 210
- Phase 4
- 180
- Not applicable
- 128
- Unknown
- 268
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Seoul | South Korea | 175 |
| 2 | New York | United States | 171 |
| 3 | Boston | United States | 149 |
| 4 | Prague | Czechia | 149 |
| 5 | Austin | United States | 134 |
| 6 | London | United Kingdom | 129 |
| 7 | Montreal | Canada | 124 |
| 8 | Barcelona | Spain | 119 |
| 9 | Philadelphia | United States | 117 |
| 10 | Beijing | China | 113 |
Terminations
- Terminated
- 233
- Withdrawn
- 106
- Suspended
- 7
- Stopped for recruitment
- 2.4%91 of 3796 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05147792 Suspended | Suspended | Enrollment has been temporarily suspended out of an abundance of caution and in close consultation with trial leadership and regulatory bodies to review overall study data thoroughly following a serious adverse event. | 2031-12-31 |
| NCT07565337 Withdrawn | Withdrawn | Administrative withdrawal: This study was determined to be a continuation of \[NCT05718336\]. To avoid duplicate reporting and ensure consistent publication, this record is being consolidated into the prior study. No enrollment has occurred. | 2028-12-31 |
| NCT04600713 Withdrawn | Withdrawn | Due to logistical problems | 2028-10-31 |
| NCT07651046 Withdrawn | Withdrawn | Protocol details were entered incorrectly; study withdrawn before any enrollment. | 2028-08-31 |
| NCT06600620 Suspended | Suspended | logistical issues | 2028-08-01 |
| NCT05209165 Suspended | Suspended | Company decision | 2028-05-31 |
| NCT06182566 Withdrawn | Withdrawn | Department feasibility | 2027-07-01 |
| NCT07127900 Withdrawn | Withdrawn | For administrative reasons | 2027-04-01 |
| NCT06334250 Withdrawn | Withdrawn | Decision not to commence study. | 2026-12-31 |
| NCT04239534 Withdrawn | Withdrawn | Start-up and enrolling activities have been suspended and study closed | 2026-11-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Atrial Fibrillation trials on ClinicalTrials.gov →